Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Investigate The Clinical Efficacy And Safety of DiaPep277® in Newly Diagnosed Type 1 Diabetes Patients

NCT00615264 is registered in ClinicalTrials.gov with Andromeda Biotech Ltd. as lead sponsor.

NCT NCT00615264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00615264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Investigate The Clinical Efficacy And Safety of DiaPep277® in Newly Diagnosed Type 1 Diabetes Patients
Lead sponsor
Andromeda Biotech Ltd.
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2005
Completion date
January 31, 2012
Enrollment
457 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes